An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition

Targeting the epithelial-to-mesenchymal transition (EMT) is emerging as a novel intervention against tumor progression and metastatic dissemination, as well as the resistance to chemo- and radiotherapy displayed by multiple carcinomas. We have recently developed an immunotherapeutic approach to targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Palena, Claudia, Fernando, Romaine I, Hamilton, Duane H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929358/
https://www.ncbi.nlm.nih.gov/pubmed/24575384
http://dx.doi.org/10.4161/onci.27220
_version_ 1782304385033830400
author Palena, Claudia
Fernando, Romaine I
Hamilton, Duane H
author_facet Palena, Claudia
Fernando, Romaine I
Hamilton, Duane H
author_sort Palena, Claudia
collection PubMed
description Targeting the epithelial-to-mesenchymal transition (EMT) is emerging as a novel intervention against tumor progression and metastatic dissemination, as well as the resistance to chemo- and radiotherapy displayed by multiple carcinomas. We have recently developed an immunotherapeutic approach to target a major driver of EMT, the T-box transcription factor T (also known as brachyury). This therapeutic paradigm is currently being tested in patients with advanced carcinomas in the context of a Phase I clinical trial.
format Online
Article
Text
id pubmed-3929358
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39293582014-02-26 An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition Palena, Claudia Fernando, Romaine I Hamilton, Duane H Oncoimmunology Author's View Targeting the epithelial-to-mesenchymal transition (EMT) is emerging as a novel intervention against tumor progression and metastatic dissemination, as well as the resistance to chemo- and radiotherapy displayed by multiple carcinomas. We have recently developed an immunotherapeutic approach to target a major driver of EMT, the T-box transcription factor T (also known as brachyury). This therapeutic paradigm is currently being tested in patients with advanced carcinomas in the context of a Phase I clinical trial. Landes Bioscience 2014-01-01 /pmc/articles/PMC3929358/ /pubmed/24575384 http://dx.doi.org/10.4161/onci.27220 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Palena, Claudia
Fernando, Romaine I
Hamilton, Duane H
An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
title An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
title_full An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
title_fullStr An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
title_full_unstemmed An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
title_short An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
title_sort immunotherapeutic intervention against tumor progression: targeting a driver of the epithelial-to-mesenchymal transition
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929358/
https://www.ncbi.nlm.nih.gov/pubmed/24575384
http://dx.doi.org/10.4161/onci.27220
work_keys_str_mv AT palenaclaudia animmunotherapeuticinterventionagainsttumorprogressiontargetingadriveroftheepithelialtomesenchymaltransition
AT fernandoromainei animmunotherapeuticinterventionagainsttumorprogressiontargetingadriveroftheepithelialtomesenchymaltransition
AT hamiltonduaneh animmunotherapeuticinterventionagainsttumorprogressiontargetingadriveroftheepithelialtomesenchymaltransition
AT palenaclaudia immunotherapeuticinterventionagainsttumorprogressiontargetingadriveroftheepithelialtomesenchymaltransition
AT fernandoromainei immunotherapeuticinterventionagainsttumorprogressiontargetingadriveroftheepithelialtomesenchymaltransition
AT hamiltonduaneh immunotherapeuticinterventionagainsttumorprogressiontargetingadriveroftheepithelialtomesenchymaltransition

Ejemplares similares